Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Cenovus Energy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $29.71 (market cap $5.07B), while Cenovus Energy Inc trades at $30.21 (market cap $55.00B). The key difference: Cenovus Energy Inc is far larger — about 10.8× ACADIA Pharmaceuticals Inc.'s market cap, and Cenovus Energy Inc pays a 2.09% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | CVE | |
|---|---|---|
Market Cap | $5.07B | $55.00B |
Sector | Health | Energy |
52-Week High | $29.41 | $31.80 |
52-Week Low | $20.06 | $14.83 |
Enterprise Value | $4.19B | $61.08B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACADIA Pharmaceuticals (ACAD) trades at $29.39, up 0.62% on the day, with strong earnings momentum after Q2 2026 results beat expectations. The stock shows bullish technical signals from moving averages, though oscillators suggest potential overbought conditions. Revenue growth has been robust, rising from $517M in 2022 to $1.07B in 2025, with net income turning positive and margins expanding significantly. Recent news highlights FDA Fast Track designation for remlifanserin and raised 2026 revenue guidance.
Outlook remains positive driven by product sales growth and pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Analyst consensus is strongly bullish with a $33.89 price target, indicating ~15% upside. Investment appeal hinges on execution of commercial strategy and successful drug development.
Cenovus Energy (CVE) trades at $29.56, up 4.64% with bullish technical momentum. The stock shows strong fundamentals with attractive valuation ratios (P/E 11.56, EV/EBITDA 5.77) and solid profitability (ROE 20.96%). Recent Q2 2026 earnings matched estimates with record oil sands production driving operational strength. Analyst consensus leans positive with 40.7% buy ratings despite mixed quarterly performance.
CVE presents value opportunity with robust cash flow generation and production growth, though faces commodity price volatility risks. Wall Street sentiment remains cautiously optimistic with institutional accumulation supporting upside potential. Key risks include oil price dependency and refining margin pressures that could impact earnings stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
